A

s more lawmakers support importation in response to the rising cost of medicines, four former commissioners of the US Food and Drug Administration wrote an open letter to Congress on Thursday to warn that the idea is “a complex and risky approach.”

The former agency heads argue that routine importation is “likely to harm patients and consumers and compromise the carefully constructed system that guards the safety of our nation’s medical products.” And they maintain that the ‘closed distribution system’ overseen by the FDA ensures that good manufacturing practices are followed and the quality of the supply chain is protected.

Unlock this article by subscribing to STAT Plus today. Try it FREE for 30 days and cancel anytime!

SUBSCRIBE TODAY

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Morning Rounds newsletter

Your daily dose of what’s new in health and medicine.

Privacy Policy